Clinical Trial Update: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating neoadjuvant dabrafenib, trametinib and/or pembrolizumab in BRAF-mutant resectable stage III melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Pembrolizumab (pembrolizumab)
• Trametinib (trametinib)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Melanoma | Phase 2 | Status: UNKNOWN